TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO DMARDS AND/OR TNF INHIBITORS: ACT-SURE PRELIMINARY RESULTS

被引：0
|
作者：
Tymms, K. [1 ]
Littlejohn, G. [2 ]
Bossingham, D. [3 ]
Griffiths, H. [4 ]
Bagga, H. [5 ]
Clemens, L. [6 ]
Smith, M. [7 ]
Bird, P. [8 ]
Bykerk, V
机构：
[1] Canberra Rheumatol, Canberra, ACT, Australia
[2] Monash Med Ctr, Clayton, Vic 3168, Australia
[3] Cairns Base Hosp, Cairns, Qld, Australia
[4] Barwon Rheumatol Ctr, Geelong, Vic, Australia
[5] Mid N Coast Arthrit Clin, Coffs Harbour, NSW, Australia
[6] St Vincents Hosp, Fitzroy, Vic 3065, Australia
[7] Repatriat Gen Hosp, Daw Pk, SA, Australia
[8] Combined Rheumatol Practice, Kogarah, NSW, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2011年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] ACT-SURE PRELIMINARY RESULTS: TOCILIZUMAB TREATMENT OF PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO DMARDS AND/OR TNF INHIBITORS IN A SETTING CLOSE TO CLINICAL PRACTICE
    Bykerk, Vivian P.
    Alvaro-Gracia, Jose
    Roman Ivorra, Jose Andres
    Nurmohamed, Michael T.
    Pavelka, Karel
    Bernasconi, Corrado
    Stancati, Andrea
    Sibilia, Jean
    Oestoer, Andrew
    [J]. RHEUMATOLOGY, 2011, 50 : 124 - 125
  • [2] Safety and efficacy of Tocilizumab as monotherapy or in combination with MTX in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: Subanalysis of the Austrian and Swiss patients of the ACT-SURE study
    Ruediger, Mueller
    Winfried, Graninger
    Paris, Sidiropoulos
    Christoph, Goger
    Johannes, von Kempis
    [J]. SWISS MEDICAL WEEKLY, 2016, 146 : 8S - 8S
  • [3] TOCILIZUMAB IMPROVES SYSTEMIC SYMPTOMS OF RHEUMATOID ARTHRITIS IN PATIENTS WITH AN INADEQUATE RESPONSE TO DMARDs
    Bonfiglioli, R.
    Smolen, J.
    Kissel, K.
    Cocco, Maldonado J.
    Ramos-Remus, C.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S32 - S32
  • [4] RETENTION OF TOCILIZUMAB AS MONOTHERAPY VERSUS TNF INHIBITORS WITH CONVENTIONAL SYNTHETIC DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS: A STUDY FROM THE TOCERRA COLLABORATION
    Lauper, K.
    Nordstrom, D. C.
    Pavelka, K.
    Hernandez, V.
    Santos, M. J.
    Rotar, Z.
    Iannone, F.
    Codreanu, C.
    Lukina, G.
    Gale, S. L.
    Sarsour, K.
    Pethoe-Schramm, A.
    Courvoisier, D. S.
    Gabay, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 850 - 851
  • [5] Benefit of Continuing Treatment Beyond 12 Weeks in Patients With Rheumatoid Arthritis Treated With Tocilizumab and DMARDs Who Had Previous Inadequate Responses to DMARDs or TNF Inhibitors
    Keystone, Edward
    John, Ani
    Wong, Kar
    [J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1333 - 1333
  • [6] Tocilizumab in Patients with Active Rheumatoid Arthritis and Inadequate Response to DMARDs and/or TNF Inhibitors: A Large, Open-Label Study Close to Clinical Practice
    Lunzer, R.
    [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2012, 19 (04): : 195 - 195
  • [7] Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
    Mueller, Ruediger B.
    Graninger, Winfried
    Sidiropoulos, Paris
    Goger, Christoph
    von Kempis, Johannes
    [J]. CLINICAL RHEUMATOLOGY, 2017, 36 (10) : 2187 - 2192
  • [8] Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
    Ruediger B. Mueller
    Winfried Graninger
    Páris Sidiropoulos
    Christoph Goger
    Johannes von Kempis
    [J]. Clinical Rheumatology, 2017, 36 : 2187 - 2192
  • [9] MEDIAN TIME TO LOW DISEASE ACTIVITY IS SHORTER IN TOCILIZUMAB COMBINATION THERAPY WITH CSDMARDS AS COMPARED TO MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSES TO CSDMARDS AND/OR TNF INHIBITORS: SUBANALYSIS OF THE SWISS AND AUSTRIAN PATIENTS FROM THE ACT-SURE STUDY
    Mueller, R.
    Graninger, W.
    Sidiropoulos, P.
    Goger, C.
    Von Kempis, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 579 - 579
  • [10] Rheumatoid factor level unexpectedly increased by the tocilizumab in rheumatoid arthritis patients with good clinical response and previous inadequate response to TNF inhibitors
    Kaliterna, D. Martinovic
    Radic, M.
    Perkovic, D.
    Krstulovic, D. Marasovic
    Marinovic, I.
    Boric, K.
    Aljinovic, J.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126
12345